Anemia of Chronic Kidney Disease
Pipeline by Development Stage
Drug Modality Breakdown
Hematology is a $3.6B market dominated by a single blockbuster (IMBRUVICA at 65% share) with moderate consolidation among 15 companies.
Key Trends
- IMBRUVICA monopoly creates revenue concentration risk but sustained peak-cycle performance
- Multiple patent cliffs 2027-2030 will drive significant biosimilar/generic competition
- 1,109 active trials signal robust pipeline activity in underexplored indications like myelofibrosis and platelet disorders
Career Verdict
Hematology offers solid commercial and medical affairs opportunities in a stable, high-margin market, but pipeline diversity remains limited outside oncology-adjacent BTK inhibitors.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | IMBRUVICA (ibrutinib) | AbbVie | $2.4B | 65% | Peak | Stable | 9.0yr |
| 2 | PROMACTA (eltrombopag olamine) | Novartis | $558M | 15% | LOE Approaching | Declining | 1.7yr |
| 3 | AURYXIA (ferric citrate) | Ipsen | $183M | 5% | Peak | Stable | 4.2yr |
| 4 | OXBRYTA (voxelotor) | Pfizer | $101M | 3% | Peak | Growing | 11.4yr |
| 5 | DOPTELET (avatrombopag maleate) | Unknown | $96M | 3% | LOE Approaching | Declining | 1.2yr |
Drug Class Breakdown
dominates market, stable
multiple players, patent risk
niche, CKD-focused
sickle cell focused, growing
myeloproliferative neoplasms, early growth
legacy class, biosimilar pressure
biosimilar-saturated, mature
Career Outlook
StableHematology is a stable, mature therapeutic area with predictable commercial demand but limited innovation upside. The market is defensible by IMBRUVICA (peak through 2035) and near-term patent cliff risks (2027-2030) will create managed-care and payer expertise needs. Long-term career growth depends on successful pipeline diversification beyond BTK inhibitors and late-stage pipeline expansion.
Breaking In
Enter via Clinical Operations or Medical Affairs to build hematology disease knowledge; specialize early in rare indications (ITP, myelofibrosis) where differentiation exists.
For Experienced Professionals
Experienced professionals should target Bristol Myers Squibb, Novartis, or GSK to lead patent-cliff transition strategies and next-generation mechanism adoption (JAK, TPO agonists).
In-Demand Skills
Best For
Hiring Landscape
Hematology hiring is concentrated in Commercial (24 roles, $201K avg) and Medical Affairs (15 roles, $204K avg) functions, reflecting a mature market focused on market penetration and specialist education. Labcorp, Bristol Myers Squibb, and Regeneron lead hiring, suggesting demand in diagnostics, R&D, and rare disease support. Notably low R&D hiring (7 roles, $147K avg) indicates limited pipeline-driven growth outside established players.
Top Hiring Companies
By Department
Commercial and Medical Affairs roles offer highest compensation and most openings; entry-level clinical operations salaries lag at $91K, while R&D roles are scarce and lower-paid.
On Market (1)
Approved therapies currently available
Competitive Landscape
11 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 38 trials with date data
Clinical Trials (38)
Total enrollment: 14,773 patients across 38 trials
A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents
Vafseo Outcomes In-Center Experience
A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.
Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease
Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis
CKD-11101 Phase 3 SC Study
Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents
Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat
A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet
Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin
Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
Related Jobs in Hematology
Account Operations Manager - Southeast
Manager, Global Regulatory Operations
Associate Director of Strategic Accounts, Hematology – Great Lakes
Quality Assurance Specialist
Director, Contracts Counsel
SALES REP SR - Hematologia (São Paulo)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.